In the past few years pharmaceutical companies have developed a string of new Alzheimer’s drugs called anti-amyloids, which target amyloid plaques in patients’ brains. These plaques are one of the key biomarkers of the disease.
The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous controversy. The FDA approved the drug despite little evidence that it actually slowed cognitive decline in patients. Biogen, the maker of Aduhelm, pulled the plug on further research or sales of the drug last month.
In January 2023 The FDA approved another anti-amyloid medication from Biogen, lecanemab, sold under the brand name Leqembi. This time, there was much stronger evidence. Clinical trial results showed that the drug showed a modest improvement in cognitive decline in the early phases of the disease. But the drug comes with risks, including brain swelling and bleeding.
Most recently, at the beginning of March, the FDA delayed approval of another anti-amyloid drug, donanemab, created by Eli Lilly. The FDA said it will be conducting an additional review to further scrutinize the study design and efficacy data.
From the outside looking in, these Alzheimer’s drugs appear to be mired in controversy. How well do they actually work? And why has there been so much back and forth with the FDA?
To answer those questions and more, guest host Arielle Duhaime-Ross talks with Dr. Jason Karlawish, professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, and co-director of the Penn Memory Center.
Transcripts for each segment will be available after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
668: Flame Retardant From Cocoa Pod Husks | The Oozy Physics Of Oobleck
667: The Military’s Carbon Footprint Is A Hidden Cost Of Defense
666: High Energy Cosmic Ray Detected | These Penguins Are The Masters Of Microsleeping
665: COP28 Climate Conference Ends | Why Are Some People Affected By Seasonal Affective Disorder?
664: A Celebration Of The 2023 Christmas Bird Count
663: Surfing Particles Can Supercharge Northern Lights
662: The (Not So) Easy Guide To Getting To Space
663: The Women Astronomers Who Captured the Stars
662: Quercetin May Cause Red Wine Headaches | Worsening Wildfires Are Undoing Air Quality Progress
661: Speaking Multiple Languages Changes The Way You Think
660: Social Connections Keep Us Physically and Mentally Healthy As We Age
661: Women Were Also Skilled Hunters In Ancient Times
658: An AI Leader’s Human-Centered Approach To Artificial Intelligence
659: COP28 Host Had Plans to Promote Oil and Gas | Researchers Detected Cicada Emergence With Fiber-Optics
656: Ralph Nader Reflects On His Auto Safety Campaign, 55 Years Later
654: What’s That Smell? An AI Nose Knows
655: Jane Goodall On Life Among Chimpanzees
654: The ‘Wet-Dog Shake’ And Other Physics Mysteries
657: Ig Nobel Prizes | Stop Flushing Your Health Data Down The Toilet
653: The West’s Wild Horses | Artist Explores History Of Humans Genetically Modifying Pigs
Create your
podcast in
minutes
It is Free
The Modern West
Just Dumb Enough Podcast
Voices of Misery Podcast
House of Whimsical Terror
Stuff You Should Know
Timcast IRL